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Abstract
Objective
We investigated the association of genetic polymorphisms in chemokine and chemokine
receptor genes with poor immunological recovery in HIV patients starting combined antire-
troviral therapy (cART) with low CD4 T-cell counts.
Methods
A case-control study was conducted in 412 HIV-infected patients starting cART with CD4 T-
cell count <200 cells/μL and successful viral control for two years. CD4 count increase
below 200 cells/μL after two years on cART was used to define INR (immunological non-
responder) patients. Polymorphisms in CXCL12, CCL5 and CCR2 genes were genotyped
using sequenom’s MassARRAY platform.
Results
Thirty two percent (134/412) of patients were classified as INR. After adjusting by age, route
of HIV infection, length of infection before cART and viral hepatitis coinfection, CCR2
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rs1799864-AG genotype was significantly associated with INR status (OR [95% CI]: 1.80
[1.04–3.11]; p = 0.04), and CXCL12 rs1801157-TT genotype showed a trend (OR [95% CI]:
2.47 [0.96–6.35]; p = 0.06).
Conclusions
CCR2 rs1799864-AG or CXCL12 rs1801157-TT genotypes influence on the probability of
poor CD4 recovery in the population of HIV patients starting cART with low CD4 counts.
Genotyping of these polymorphisms could be used to estimate the risk of poor CD4 restora-
tion, mainly in patients who are diagnosed late in the course of infection.
Introduction
The progressive loss of CD4 T cells is the hallmark of HIV pathogenesis. Treatment of HIV
infection with combination antiretroviral therapy (cART) usually results in suppression of
viral replication to undetectable levels and increasing CD4 T cell counts. However, despite
suppression of viral replication, approximately 30% of HIV-infected patients do not achieve an
optimal CD4 T-cell recovery [1,2] and these individuals are referred to as immunological non-
responders (INR) [3]. This phenomenon is of clinical relevance because the persistently low
CD4 T cell counts are associated with a high risk of disease progression, AIDS and non-AIDS
clinical events and death [4]. Mechanisms underlying the INR status are not well understood.
Nadir CD4 T cell count (defined as the lowest point to which the CD4 count has dropped) at
the beginning of cART is the most common determinant of poor immune recovery [5,6] rep-
resenting an important concern because of the high proportion of patients showing CD4 T-
cell counts below 350 cells/mm3 or even<200 cells/mm3 at the moment of diagnosis [7].
Several other factors have been involved on poor CD4 recovery upon successful cART such
as older age [8], co-infection with HCV [9], high CD4+ T cell apoptosis [6], chronic immune
activation [10,11], or poor thymic output [12]. Moreover, some studies have suggested that
variability between individuals in the capacity of the immune system to recover after antiretro-
viral therapy is attributed to the genetic variations among HIV-infected patients [13]. Poly-
morphisms in genes encoding different immune-regulating molecules [14], and molecules
involved in T-cell homeostasis [15] and cellular metabolism [16] have been associated with the
extent of CD4 T cell recovery during cART.
Further, genetic polymorphisms in genes coding for chemokines and chemokine receptors
have been demonstrated to influence both HIV transmission and disease progression [17–19].
Genetic polymorphisms in chemokines CCL5 (RANTES) and CXCL12 (SDF1), which act as
potent blockers of HIV infection by competing with the virus for binding to CCR5 and CXCR4
receptors respectively, have been described to be associated with HIV disease progression. For
instance, C allele of the intronic polymorphism rs2280789 in the CCL5 gene has been associ-
ated with accelerated progression to AIDS by down regulating CCL5 gene transcription [20].
Homozygosity for A allele of polymorphism rs1801157 in CXCL12 gene has been associated
with slower progression to AIDS [21], although this finding has not been confirmed by others
[18, 22]. Regarding genetic variants in chemokine receptors, heterozygosity or homozytosity
of A allele of polymorphism rs1799864 (V64I) in the CCR2 gene has been associated with
slower progression to AIDS [23].
The contribution of the genetic variants mentioned above in the context of antiretroviral
treatment has been less explored and the results are unclear [24–26]. Furthermore, the
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potential influence of these genetic variants in the phenomenon of immunological non
response in the special population of patients starting cART with low CD4 counts has not been
explored so far. Our goal in this study was to investigate the association of host genetic poly-
morphisms in CCL5, CXCL12 and CCR2 genes with the phenomenon of immunological dis-
cordance in a cohort of HIV infected patients starting cART with very low CD4 T-cell counts
and maintaining complete suppression of viral replication after treatment.
Materials and methods
Study population
This is a retrospective, case-control study for which we screened 6109 HIV infected patients
included in the cohort of the Spanish AIDS Research Network (CoRIS), a multicentre cohort
with clinical data and biological samples of HIV-positive subjects launched in 2004 [27,28].
The majority of samples were kindly provided by the Spanish HIV BioBank integrated in the
Spanish AIDS Research Network (RIS) [29]. The inclusion criteria were (Fig 1): a) patients ini-
tiating their first cART regimen; b) CD4 T-cell counts at the initiation of cART<200 cells/μL;
c) complete viral suppression (plasma HIV-RNA <50 copies/mL) during 2 years of therapy; d)
regular follow up of CD4 counts and HIV viral load; e) having a DNA sample available for
analysis. Using these inclusion criteria, 361 patients were selected from the CoRIS cohort. In
addition, a cohort of 51 patients meeting the same inclusion criteria was provided by the HIV
cohort of the Institut de Recerca de la Sida IrsiCaixa-HIVACAT, Institut d’Investigació en
Ciènces de la Salut Germans Trias i Pujol (Badalona, Spain). Protocols were approved by insti-
tutional ethical committees (Germans Trias I Pujol Hospital ethical committee and CoRIS eth-
ical committee) and all individuals provided written an informed consent to participate in the
study.
Polymorphisms genotyping
We selected three chemokine and chemokine receptor polymorphisms: rs2280789 located in
CCL5 gene, rs1801157 located in CXCL12 gene and rs1799864 located in CCR2 gene. All of
these polymorphisms have a minor allele frequency (MAF) higher than 5% in the CEU (Utah
residents with ancestry from Northern and Western Europe) and Tuscan (Italy) populations
according to 1000 Genomes Project database (http://www.internationalgenome.org/) [30].
Moreover, as a reference group, a control healthy population consisting of 107 individuals of
Iberian origin (Iberian populations in Spain, IBS) was obtained from this same database.
Genomic DNA was extracted from cryopreserved peripheral blood mononuclear cells
(PBMCs) using a QIAamp DNA kit (Qiagen, Barcelona, Spain) following manufacturer’s
instructions. DNA samples were genotyped at the Spanish National Genotyping Center
(CeGen; http://www.usc.es/cegen/). Genotyping was performed by using sequenom’s Mas-
sARRAY platform (San Diego, CA, USA) using the Iplex Gold assay design system. The quality
control was performed according to the CeGen criteria and all samples were made in duplicate
on each plate. Moreover, a negative control to exclude DNA contamination and positive con-
trol to ensure a technically correct laboratory process were included in each assay plate.
Outcome variable
CD4 T-cell count increase (ΔCD4) below or above 200 cells/μL after two years on cART and
suppressed viral replication was the outcome variable. Immunological non-responders (INR)
patients were defined as patients showing a ΔCD4 <200 cells/μL, and immunological respond-
ers (IR) patients as patients showing a ΔCD4�200 cells/μL.
CCR2 and CXCL12 SNPs and HIV immunological non-responders
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Statistical analysis
To describe study population, median and interquartile range (IQR) was employed. Nonpara-
metric tests (Mann-Whitney U Test for continuous variable and Chi-square (x2) or Fisher‘s
exact test for categorical variables) were used to compare different groups of subjects. Allelic
and genotypic frequencies and association studies for individual polymorphisms were per-
formed using the web tool SNPStats (https://www.snpstats.net/start.htm) [31]. SNPs were eval-
uated for Hardy-Weinberg equilibrium (HWE), considering p>0.05. Association of the
different SNPs variants with INR status was tested using five different models: recessive,
Fig 1. Flow chart of inclusion criteria of patients. Flow chart showing the inclusion criteria and the sequential
strategy of selection of patients included in the study. Numbers inside the boxes indicate the number of patients
selected after each step in the selection process.
https://doi.org/10.1371/journal.pone.0214421.g001
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dominant, over-dominant, log-additive and co-dominant. Multivariate logistic regression
analysis was used to test the association of CCL5, CXCL12 and CCR2 SNPs with INR status,
adjusting by other clinical and epidemiological variables that showed significant association
with INR status. Statistical analyses were performed using SPSS software version 15 (SPSS Inc.,
Chicago, IL, USA). All p-values were considered significant when <0.05.
Results
Study population
A total of 412 patients meeting all the inclusion criteria were analyzed. Of them, 134 patients
were classified as INR because they had a CD4 increase (ΔCD4) below 200 cells/μL after 2
years on cART. The remaining 278 patients were classified as IR because they showed a ΔCD4
equal or above 200 cells/μL after the same period of cART. As expected, there were significant
differences in ΔCD4 between INR and IR groups of patients (133 [73–174] and 342 [267–467]
cells/μL in INR and IR groups respectively; p<0.0001). Table 1 shows different characteristics
in the total population of patients and in INR and IR groups. There were no differences in
CD4 T-cell count pre-cART between INR and IR (99 [41–148] and 107 [41–162] cells/μL
respectively, p = 0.4). However, significant differences between INR and IR groups were
observed for age (42 [36–48] vs. 39 [32–47] years respectively, p = 0.009); length of infection
before cART (1 [1–2] and 1 [1–1] years respectively, p = 0.029); prevalence of infection with
hepatitis viruses (18% vs. 10% respectively, p = 0.018); and transmission category with more
prevalence of injected drug users in INR than IR (22% vs. 11% respectively, p = 0.003).
Alleles and genotypes distribution of CCL5 rs2280789, CXCL12 rs1801157,
and CCR2 rs1799864 polymorphisms
The distribution of CCL5 rs2280789, CCR2 rs1799864, and CXCL12 rs1801157 alleles and
genotypes in INR and IR patients is shown in Table 2. All three polymorphisms analyzed had a
Table 1. Characteristics of study population.
Characteristics All patients (n = 412) INR patients (n = 134) IR patients (n = 278) p-values�
Age (years) 40 [34–47] 42 [36–48] 39 [32–47] 0.009
Length of HIV infection before cART (months) 3 [1–23] 3 [1–56] 3 [1–14] 0.045
CD4 counts at baseline (cells/μL) 104 [41–159] 99 [41–148] 107 [41–162] 0.405
CD4 increase after 2 years on cART (cells/μL) 268 [177–400] 133 [73–174] 342 [267–467] <0.0001
Coinfection with HCV or HBV. n (%) 52/412 (13) 24/134 (18) 28/278 (10) 0.018
Transmission category 0.003
Sexual 329/385 (85) 93/120 (78) 236/265 (89)
Parenteral 56/385 (15) 27/120 (22) 29/265 (11)
Gender (male). N˚ (%) 324/412 (79) 112/134 (84) 212/278 (76) 0.089
cART regimen. N˚ (%) 0.721
PI-based regimen 127/411 (31) 40/134 (30) 87/277 (31)
Non PI-based regimen 284/411 (69) 94/134 (70) 190/277 (69)
Ethnic origin. N˚ (%) 0.062
Caucasian 318/394 (81) 108/124 (87) 210/270 (78)
African 25/394 (6) 7/124 (6) 18/270 (7)
Latin American 51/394 (13) 9/124 (7) 42/270 (15)
Data are given as median and interquartile range [IQR], unless otherwise indicated. INR: immunological non responders. IR: immunological responders. cART:
combination antiretroviral therapy. HCV: hepatitis C virus. HBV: hepatitis B virus.
� p-values for the comparison between IR and INR patients (Mann-Whitney U test or Chi-square test as appropriate)
https://doi.org/10.1371/journal.pone.0214421.t001
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minimum allele frequency (MAF)> 0.05 and satisfied the HWE (p>0.05). Overall, both alleles
and genotypes distribution of all three polymorphisms was similar between groups.
The CCL5 rs2280789 genotype GG was very rare in both IR (3%) and INR (2%) patients.
Seventy six percent of IR and 72% of INR where homozygous for rs2280789 A allele, whereas
21% percent of IR and 26% of INR patients were heterozygous for rs2280789 (p = 0.54).
Regarding CXCL12 rs1801157, genotype TT frequency was low in both IR (3%) and INR (8%)
patients. Sixty two percent of IR and 60% of INR patients carried rs1801157 CC genotype,
whereas 35% of IR and 32% of INR patients carried rs1801157 genotype CT (p = 0.12). The
distribution of CCR2 rs1799864 genotypes was: 1% of IR and none of INR patients carried
rs1799864 AA genotype. Eighty three percent of IR and 78% of INR patients were homozygous
for rs1799864 G allele, whereas the proportion of individuals carrying rs1799864 AG genotype
was slightly higher in INR compared to IR patients (22% and 16% respectively, p = 0.09).
In addition, alleles and genotypes frequencies of these three polymorphisms in our study
population were very similar to those reported by 1000 genomes database in the Iberian popu-
lations in Spain (IBS) [30], except for the CCL5 rs2280789 AA genotype (p = 0.04) (S1 Table).
Association of CCL5 rs2280789, CXCL12 rs1801157 and CCR2 rs1799864
polymorphisms with INR status
Using SNPstats web tool [31], we first tested the best association model with INR status for the
different SNPs analyzed. The best models of association fitting our data were a recessive model
for CXCL12 rs1801157 and an over-dominant model for CCR2 rs1799864 polymorphisms,
whereas CCL5 rs2280789 showed no association with INR with any of the models tested.
According to these models of association, patients were stratified into two groups according to
CXCL12 rs1801157 polymorphism into those carrying TT genotype and those carrying CT or
CC genotype; and according to CCR2 rs1799864 polymorphism into those carrying AG geno-
type and those carrying AA or GG genotypes.
Next, we performed both univariate and multivariate logistic regression analysis. By univar-
iate logistic regression, CXCL12 rs1801157 TT genotype (OR: 2.40 [0.96–6.13]; p = 0.05) and
CCR2 rs1799864 AG genotype (OR: 1.50 [0.91–2.58]; p = 0.10) showed a trend to be associated
to INR status (Table 3). However, after correcting by age, length of infection, co-infection with
hepatitis viruses and transmission route, variables that presented significant differences
between INR and IR groups (Table 1), the multivariate logistic analysis showed that CCR2
rs1799864 AG genotype was significantly and independently associated to INR status (OR:
1.80 [1.04–3.11]; p = 0.036) and CXCL12 rs1801157 TT genotype showed a clear trend (OR:
2.47 [0.96–6.13]; p = 0.063) (Table 3).
Discussion
The immunological non-responders are a group of HIV patients who do not achieve an opti-
mal CD4 T-cell recovery despite receiving cART and maintaining complete viral suppression
[3]. Understanding the host factors influencing this impaired immune recovery despite cART,
may be critical to design appropriate strategies aimed to improve the immune status in these
patients.
Given the pivotal role of chemokines and chemokine receptors in the lymphocyte traffic
and its known effect in HIV disease progression, in this study we explored the potential associ-
ation of CCL5 rs2280789, CXCL12 rs1801157, and CCR2 rs1799864 polymorphisms with CD4
T-cell recovery in a particular cohort of 412 HIV infected individuals who began cART with
low CD4 T-cell counts and who maintained complete suppression of HIV plasma viremia dur-
ing 2 years on treatment. Interestingly, our results showed that CCR2 rs1799864 AG and
CCR2 and CXCL12 SNPs and HIV immunological non-responders
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CXCL12 rs1801157 TT genotypes were associated with a higher probability of having poor
CD4 T-cell recovery in HIV patients despite complete viral suppression with cART. No
Table 2. Summary of alleles and genotype frequencies for CCL5 rs2280789, CCR2 rs1799864 and CXCL12 rs1801157 polymorphims in the study population.
SNP alleles and genotypes All patients (n = 412) IR (n = 278) INR (n = 134) p-value
CCL5 rs2280789
Alleles
A 86% 86% 85% 0.30
G 14% 14% 15%
Genotypes
AA 75% 76% 72% 0.54
AG 23% 21% 26%
GG 2% 3% 2%
HWE (p-value) 0.41 0.13 0.74
CXCL12 rs1801157
Alleles
C 78% 79% 76% 0.20
T 22% 21% 24%
Genotypes
CC 61% 62% 60% 0.12
CT 34% 35% 32%
TT 5% 3% 8%
HWE (p-value) 1 0.36 0.23
CCR2 rs1799864
Alleles
G 90% 91% 89% 0.20
A 10% 9% 11%
Genotypes
AA 1% 1% 0% 0.09
GA 18% 16% 22%
GG 81% 83% 78%
HWE (p-value) 0.78 0.47 0.37
INR: immunological non responders patients; IR: immunological responders patients; HWE: Hardy-Weinberg equilibrium.
p-values for the comparison between IR and INR patients (Chi-square test)
https://doi.org/10.1371/journal.pone.0214421.t002
Table 3. Association of CXCL12 rs1801157 (recessive inheritance model) and CCR2 rs1799864 (over-dominant inheritance model) genotypes with INR status.
Frequencies Univariate analysis Multivariate analysis
Genotypes IR (n = 278) INR (n = 134) OR [95% CI] p-value OR [95% CI] p-valuea
CXCL12 rs1801157
TT 3% (9/278) 8% (10/134) 2.4 [0.96–6.13] 0.05 2.47 [0.96–6.35] 0.063
CC/CT 97% (269/278) 92% (123/134) 1 1
CCR2 rs1799864
AG 16% (44/278) 22% (30/134) 1.5 [0.91–2.58] 0.10 1.80 [1.04–3.11] 0.036
GG/AA 84% (234/278) 78% (104/134) 1 1
IR: immunological responders patients, INR: immunological non-responders patients, OR: Odds Ratio; CI: confidential interval
a p-values were calculated by logistic regression adjusted by age, length of infection before cART, transmission route, and hepatitis co-infection.
https://doi.org/10.1371/journal.pone.0214421.t003
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significant association was found for CCL5 rs2280789 polymorphism, suggesting that this
polymorphism has no effect on CD4 T-cell recovery after cART, in contrast with the results of
a previous study that found a significant association for this same polymorphism with HIV
disease progression in the absence of therapy [20]. However, given the different scenarios
(CD4 T-cell recovery after therapy versus CD4 T-cell loss in the absence of therapy), the results
of our study are not contradictory with the previous study.
The role of CCR2 gene polymorphisms on CD4 T-cell recovery in the context of cART has
been poorly studied and the results still remain unclear. The majority of studies investigating
the effect of the CCR2 gene polymorphisms in progression of HIV patients receiving antiretro-
viral therapy have reported no influence of rs1799864 genotypes on CD4 T-cell gains [25, 26,
32, 33]. However, another study reported that carriage of CCR2 rs1799864-A allele was associ-
ated with immunological outcome after initiation of cART [34]. In partial agreement with this
last study, results of our study showed a clear association between CCR2 rs1799864 genotype
and the probability of presenting an INR phenotype after cART. However, the association we
found was with CCR2 rs1799864 AG genotype and not with CCR2 rs1799864 A allele, probably
due to the very low prevalence of CCR2 rs1799864 AA genotype in our study population (only
1% of the IR patients and none in the INR patients). Moreover, Rigato et al found that A allele
was associated with better inmmunological outcome, in contrast with our results showing a
poorer outcome in patients with AG genotype. Interestingly, Rigato et al.[34] also found lower
level of CD4 restoration in those individuals carrying CCR2 rs1799864 AG genotype, although
differences did not reach significance likely due to a much more limited sample size of their
study compared to ours. Surprisingly, the protective effect of CCR2 rs1799864 A allele reported
by Rigato et al was revealed only when combined with CCR5-D32 polymorphism [34], what is
in contrast with a poorer outcome of AG individuals compared with AA individuals observed
in this same study [34]. Clearly the very low prevalence of rs1799864 AA genotype in our
study precludes finding the existence of an association between rs1799864 A allele and INR
phenotype and thus further studies with larger cohorts of patients, including a greater number
of individuals carrying rs1799864 AA genotype, are warranted to analyze the true role of this
allele on CD4 restoration after cART.
Regarding the discordant findings between our study and previous studies reporting no
association of CD4 restoration with CCR2 gene variation, differences in the size of cohorts,
length of follow-up, study design, pre-cART CD4 counts and ethnic background, among oth-
ers, may be involved in these discordant findings. It is important to highlight that in contrast
to previous studies analyzing CCR2 polymorphisms, our study included a homogeneous popu-
lation in terms of cART exposure (all patients were naïve for cART when included in the
study) and of baseline CD4 counts (including only patients who started treatment with very
low CD4 T-cell counts, <200 cells/μL). It should also be taken into account that we performed
the association analysis adjusting by clinical and epidemiological variables associated with the
phenomenon of INR such as age [8], co-infection with HCV [9] or length of infection before
treatment, what gives a strong significance to our findings.
The rs1799864 variation results in amino acid substitution from Valine to Isoleucine (V64I)
at position 64 in the transmembrane domain of CCR2 protein [23]. There is not a consensus
about the true role of CCR2 polymorphisms in the HIV disease progression. Some HIV virus
strains can use this chemokine receptor to infect cells and it is unclear why a single amino acid
substitution in a minor co-receptor could affect HIV disease progression. Curiously, an in
vitro study has shown that both wild-type CCR2 and the mutated (V64I) version of the recep-
tor were equally permissive for HIV infection regardless of viral tropism, were expressed at
similar levels on the cell surface and were equally effective acting as viral co-receptors and as
chemokine receptors, suggesting that this variation probably has neither a protective nor a
CCR2 and CXCL12 SNPs and HIV immunological non-responders
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deleterious effect in the course of HIV infection [35]. A potential explanation could be that
this polymorphism acts simply as a tag-SNP that is in linkage disequilibrium with another
polymorphism responsible for this association. In line with this, a previous study reported that
rs1799864 CCR2 polymorphism is in complete linkage disequilibrium with a C to T substitu-
tion on CCR5 regulatory region at position 59653 [36]. All individuals carrying the A allele at
rs1799864 CCR2 SNP also carried the T allele at CCR5 promoter polymorphism [36]. Regard-
ing how the C to T substitution relates to CCR5 regulation, no conclusive results have been
reported so far, although Kostrikis et al in preliminary in vitro experiments showed no effect of
CCR2 rs1799864 SNP on the levels of CCR5 expression [36].
Regarding CXCL12 rs1801157 polymorphism, also evaluated in our study, the multivariate
analysis revealed that the TT genotype had a trend toward being associated with INR status in
our cohort of HIV treated patients. The lack of statistical significance is likely due to the very
low prevalence of TT genotype and thus increasing the number of individuals with this rare
genotype could potentially lead to significance for this association, although this would require
a much larger cohort of patients. In line with our results, some reports have suggested that this
genotype is associated with accelerated HIV disease progression in untreated patients [22, 37].
Daar et al. showed that untreated HIV infected individuals carrying CXCL12 rs1801157 T
allele showed a faster CD4 decline and an increased likelihood of harboring CXCR4 tropic
viruses which has been associated with an accelerated disease progression [37]. Previous stud-
ies addressing the association of CXCL12 rs1801157 variation with CD4 restoration after
cART have yielded discordant results, with some of them reporting a significant association
[26, 33] but not others [25, 34]. Several differences between our study and the above men-
tioned studies preclude a fair comparison. Differences in the study design such baseline CD4
T-cell counts before initiating cART, criteria to evaluate CD4 restoration, length of follow up
and small size of cohorts evaluated may explain the seemingly contradictory results. Since we
used a large cohort of patients homogeneous in terms of pre-cART CD4 counts and were able
to perform a multivariate analysis adjusting for several covariables that could impact on the
CD4 restoration, we feel confident with the conclusions of our study.
The CXCL12 is a proinflamatory cytokine having pleiotropic effects on chemotaxis, angio-
genesis, immune response and tumor metastasis. CXCL12 is the natural ligand of CXCR4, the
co-receptor of X4 tropic HIV infection, thus CXCL12 can inhibit entry of HIV into the CD4
cells [38]. Regarding the biological mechanisms underlying the impact of CXCL12 rs1801157
T allele on the HIV disease progression [22, 37], a previous study reported lower CXCL12
mRNA expression in carriers of T allele [39]. In line with this, another study found a clear
association between homozygosity for T allele and low plasma levels of CXCL12 protein that
could diminish the competition with HIV to CXCR4 binding [40]. Interestingly, it has also
been reported that patients with CXCL12 rs1801157 T allele are more likely to carry X4-tropic
viruses [37]. Findings of these studies could explain the association of CXCL12 rs1801157 TT
genotype with poor CD4 T-cell recovery in HIV patients on cART that we found in our study.
In summary, the data of our study shows that in HIV patients starting cART with low CD4
counts, CCR2 rs1799864 AG and/or CXCL12 rs1801157 TT genotypes influences the probabil-
ity of poor CD4 T-cells recovery in spite of successful suppression of HIV replication. Interest-
ingly, this impact is independent of other well known factors associated to the INR status and
thus genotyping of these two polymorphisms could add prognostic value to detect those
patients with higher risk of poor CD4 restoration, in a population of patients that is growing
due to the increasing proportion of late HIV diagnosis.
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